Clinical manifestations and outcomes in 17 cases of Stevens-Johnson syndrome and toxic epidermal necrolysis.
about
Hematological abnormalities and the use of granulocyte-colony-stimulating factor in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis.Retrospective analysis of stevens-johnson syndrome and toxic epidermal necrolysis over a period of 10 years.Epidemiology and risk factors for drug allergy.Lamotrigine-induced toxic epidermal necrolysis in a young epileptic.Toxic epidermal necrolysis: a retrospective analysis of 17 cases from central TunisiaHigh-dose intravenous immunoglobulin in the treatment of toxic epidermal necrolysis: a study of ocular benefits.Toxic epidermal necrolysis (TEN) Lyell's syndrome.Immune response to xenobiotics in the skin: from contact sensitivity to drug allergy.Retrospective analysis of Steven Johnson syndrome and toxic epidermal necrolysis over a period of 5 years from northern Karnataka, IndiaToxic epidermal necrolysis/Stevens-Johnson syndrome: current trends in management.Recent advances of pharmacogenomics in severe cutaneous adverse reactions: immune and nonimmune mechanisms.An analysis of drug induced Stevens-Johnson syndrome.Visual loss in a patient with lamotrigine-induced cicatrizing conjunctivitis.A 2-year-old girl with Stevens--Johnson syndrome/toxic epidermal necrolysis treated with intravenous immunoglobulin.Granzyme B is elevated in autoimmune blistering diseases and cleaves key anchoring proteins of the dermal-epidermal junction.
P2860
Q33398324-8652F268-2E03-45BF-AC2B-720851069F4BQ34941716-669CB70D-004C-47B6-A9C8-08EC85EB3A48Q34976470-A56C57BB-B1C0-47A7-BCC7-C27A6D957471Q35094634-582C1BB3-7831-4F63-BD36-B7BD6F92E3FCQ35347220-72DECDB7-EC71-4979-92ED-FDA7B19103B2Q35897124-1998E5E3-2CC8-4249-8821-4A5F8DB7CF2DQ36374575-2C4A2FD4-530B-4666-840D-6E2BD47D3C46Q36546268-18A8FBFF-A0BF-45B1-95DB-D4AE2E9F3BB9Q36716717-E2BAEEBB-6A5B-43CD-9BA7-5895B33DCAE0Q36884071-11E6555D-18DB-42A8-B0F9-EB125098327BQ38457053-F0190DB8-3B1A-4DE9-B1FA-B12A81F95156Q43209784-3C17794C-CDC5-41E5-8C96-68CFE50D2D81Q44670776-481B4E6D-E4C9-4993-B18E-FAC1707CE92DQ46629397-C4AF26C0-460B-4E05-AD15-5A1BD1980171Q55428949-C9938980-5068-4898-8227-2CABE8F72B38
P2860
Clinical manifestations and outcomes in 17 cases of Stevens-Johnson syndrome and toxic epidermal necrolysis.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh
1999年學術文章
@zh-hant
name
Clinical manifestations and ou ...... nd toxic epidermal necrolysis.
@en
Clinical manifestations and ou ...... nd toxic epidermal necrolysis.
@nl
type
label
Clinical manifestations and ou ...... nd toxic epidermal necrolysis.
@en
Clinical manifestations and ou ...... nd toxic epidermal necrolysis.
@nl
prefLabel
Clinical manifestations and ou ...... nd toxic epidermal necrolysis.
@en
Clinical manifestations and ou ...... nd toxic epidermal necrolysis.
@nl
P2093
P2860
P1476
Clinical manifestations and ou ...... nd toxic epidermal necrolysis.
@en
P2093
P2860
P304
P356
10.1046/J.1440-0960.1999.00342.X
P577
1999-08-01T00:00:00Z